Add to ORKGLos derivados del ácido 5-aminosalicílico (5-ASA) son una importante alternativa terapéutica para muchos pacientes con enfermedad inflamatoria intestinal. Se han desarrollado nuevas formulaciones de 5-ASA con el objeto de lograr la liberación del fármaco en diferentes sitios del tracto gastrointestinal, tales como mesalazina, balsalazida y olsalazina. Se describen las características de las drogas con 5-ASA y sus efectos adversos.The 5-aminosalicyc acid (5-ASA) derivatives are an important therapeutic option for patients with inflammatory bowel disease. New formulations of 5-ASA have been developed with the object of achieving the releasing of the drug in different sites of gastrointestinal tract, such as mesalazine, balsalazide and olsalaz...
5-Aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number ...
Summary Inflammatory bowel disease incidence has been constantly rising for the past few decades. Cu...
5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcer...
Los derivados del ácido 5-aminosalicílico (5-ASA) son una importante alternativa terapéutica para mu...
The article is devoted to the comparative characterization of different derivatives of 5-aminosalicy...
Strong evidence has been accumulating that mesalazine (5- aminosalicylic acid, 5-ASA) represents the...
In recent years, many achievements have been realized in the therapy of inflammatory bowel disease (...
There are two forms of 5-aminosalicylic acid (5-ASA) drug delivery. First, a pro-drug form in which ...
Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune respo...
Los aminosalicilatos representan la piedra angular en el tratamiento de pacientes con enfermedad inf...
The knowledge that 5-aminosalicylic acid (5-ASA) is the active compound of sulphasalazine and that i...
clinical and pharmacokinetic aspects, with emphasis on 5-aminosalicjlic acid delivering drug
Background & Aims: 5-Aminosalicylate is the gold stan-dard for inducing remission in patients wi...
The efficacy of 5-ASA tablets is around 65 co 70% in patients with active ulcerative colitis, wherea...
The term inflammatory bowel diseases (IBD) refers to two distinct clinical entities: Crohn.s disease...
5-Aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number ...
Summary Inflammatory bowel disease incidence has been constantly rising for the past few decades. Cu...
5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcer...
Los derivados del ácido 5-aminosalicílico (5-ASA) son una importante alternativa terapéutica para mu...
The article is devoted to the comparative characterization of different derivatives of 5-aminosalicy...
Strong evidence has been accumulating that mesalazine (5- aminosalicylic acid, 5-ASA) represents the...
In recent years, many achievements have been realized in the therapy of inflammatory bowel disease (...
There are two forms of 5-aminosalicylic acid (5-ASA) drug delivery. First, a pro-drug form in which ...
Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune respo...
Los aminosalicilatos representan la piedra angular en el tratamiento de pacientes con enfermedad inf...
The knowledge that 5-aminosalicylic acid (5-ASA) is the active compound of sulphasalazine and that i...
clinical and pharmacokinetic aspects, with emphasis on 5-aminosalicjlic acid delivering drug
Background & Aims: 5-Aminosalicylate is the gold stan-dard for inducing remission in patients wi...
The efficacy of 5-ASA tablets is around 65 co 70% in patients with active ulcerative colitis, wherea...
The term inflammatory bowel diseases (IBD) refers to two distinct clinical entities: Crohn.s disease...
5-Aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number ...
Summary Inflammatory bowel disease incidence has been constantly rising for the past few decades. Cu...
5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcer...